NO20060149L - Farmasoytiske forbindelser av atorvastatin - Google Patents

Farmasoytiske forbindelser av atorvastatin

Info

Publication number
NO20060149L
NO20060149L NO20060149A NO20060149A NO20060149L NO 20060149 L NO20060149 L NO 20060149L NO 20060149 A NO20060149 A NO 20060149A NO 20060149 A NO20060149 A NO 20060149A NO 20060149 L NO20060149 L NO 20060149L
Authority
NO
Norway
Prior art keywords
atorvastatin
pharmaceutical composition
pharmaceutical compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20060149A
Other languages
English (en)
Norwegian (no)
Inventor
Kenneth Craig Waterman
Paul Evan Luner
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20060149L publication Critical patent/NO20060149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20060149A 2003-06-12 2006-01-10 Farmasoytiske forbindelser av atorvastatin NO20060149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47791703P 2003-06-12 2003-06-12
PCT/IB2004/001859 WO2004110406A1 (fr) 2003-06-12 2004-06-01 Compositions pharmaceutiques d'atorvastatine

Publications (1)

Publication Number Publication Date
NO20060149L true NO20060149L (no) 2006-03-06

Family

ID=33551780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060149A NO20060149L (no) 2003-06-12 2006-01-10 Farmasoytiske forbindelser av atorvastatin

Country Status (15)

Country Link
EP (1) EP1635788A1 (fr)
JP (1) JP2006527259A (fr)
KR (1) KR100760112B1 (fr)
CN (1) CN1805732A (fr)
AR (1) AR044660A1 (fr)
AU (1) AU2004246867A1 (fr)
BR (1) BRPI0411354A (fr)
CA (1) CA2465693A1 (fr)
CO (1) CO5640071A2 (fr)
MX (1) MXPA05012955A (fr)
NO (1) NO20060149L (fr)
RU (1) RU2325903C2 (fr)
TW (1) TW200503689A (fr)
WO (1) WO2004110406A1 (fr)
ZA (1) ZA200508204B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
CA2547216A1 (fr) * 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
KR101381076B1 (ko) 2006-03-29 2014-04-02 코와 가부시키가이샤 트리글리세리드 저하제 및 고인슐린 혈증 개선제
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
WO2011074961A1 (fr) 2009-12-18 2011-06-23 Frieslandcampina Nederland Holding B.V. Composition d'excipient de comprimé co-traité, sa préparation et son utilisation
SG181787A1 (en) * 2009-12-22 2012-07-30 Novartis Ag Formulation comprising 1 h - quinazoline - 2, 4 - dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
EP2575757A1 (fr) 2010-06-03 2013-04-10 Mahmut Bilgic Formulation hydrosoluble stable
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
CN104825449A (zh) * 2014-02-12 2015-08-12 天津药物研究院 含有阿托伐他汀钙和氨氯地平的复方组合物及其制备方法
JP6306690B2 (ja) * 2014-09-26 2018-04-04 株式会社フジクラ 光ファイバ
RU2591079C2 (ru) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии
AU2016274442B2 (en) * 2015-06-10 2021-08-05 Evonik Operations Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
US20180303799A1 (en) * 2015-10-16 2018-10-25 Shenzhen Salubris Pharmaceuticals Co., Ltd An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method
WO2023025672A1 (fr) 2021-08-25 2023-03-02 Basf Se Composition auxiliaire de compression directe
CN114674944A (zh) * 2022-03-04 2022-06-28 苏州东瑞制药有限公司 一种检测苯磺酸氨氯地平与阿托伐他汀钙复方制剂有关物质的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349364T3 (es) * 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
PL369268A1 (en) * 2001-03-27 2005-04-18 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
CA2385529A1 (fr) * 2002-05-21 2003-11-21 Bernard Charles Sherman Formulations posologiques stables contenant de l'atorvastatin calcium
WO2004056358A1 (fr) * 2002-12-20 2004-07-08 Pfizer Products Inc. Formes posologiques comprenant un inhibiteur de cetp et un inhibiteur de hmg-coa reductase

Also Published As

Publication number Publication date
CO5640071A2 (es) 2006-05-31
JP2006527259A (ja) 2006-11-30
CA2465693A1 (fr) 2004-12-12
AR044660A1 (es) 2005-09-21
MXPA05012955A (es) 2006-02-13
AU2004246867A1 (en) 2004-12-23
KR100760112B1 (ko) 2007-09-18
RU2005136743A (ru) 2006-07-27
WO2004110406A1 (fr) 2004-12-23
EP1635788A1 (fr) 2006-03-22
TW200503689A (en) 2005-02-01
KR20060025167A (ko) 2006-03-20
RU2325903C2 (ru) 2008-06-10
CN1805732A (zh) 2006-07-19
ZA200508204B (en) 2007-03-28
BRPI0411354A (pt) 2006-07-11

Similar Documents

Publication Publication Date Title
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
NO20055185L (no) Farmasoytiske sammensetninger omfattende atorvastatin fremstilt uten granulering
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
WO2002085909A8 (fr) Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
NO20060022L (no) Stabile sammensetninger av atorvastatin fremstilt ved vat granulering
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
LU92166I2 (fr) Glycopyrronium ou un de ses sels
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
WO2007078895A3 (fr) Formulations de tramadol à libération modifiée et leurs utilisations
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
SE0000303D0 (sv) Novel compounds
SI1806136T1 (sl) Medicinski sestavek za preprečevanje prehoda na operativno zdravljenje prostatične hipertrofije
NO20065196L (no) Terapeutisk kombinasjon for behandling av Alzheimers sykdom
WO2008079260A3 (fr) Promoteurs de désintégration dans des formulations de forme solide obtenues par un procédé de granulation par voie humide
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
NO20013901L (no) Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter
WO2007063428A3 (fr) Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application